We will apply to the Ministry of Health Italia for approval of HIPRO Rapid SARS-CoV-2 Antigen test kit to be distributed in Italia.
This product is cost-effective and a rapid point-of-care solution. With individually packaged buffer solutions for every test, minimizing possible buffer contamination, and the specimen used is saliva this product a valuable prospect for self testing solutions or non professional.
This saliva based antigen tests from HIPRO detects antigen based on the viral nucleocapsid protein coded by the very stable N gene and will be useful to test children due to the non-invasive sample collection technique.
Sensitivity (Positive incidence rate): 70%
Specificity (Negative incidence rate): 85,5%
Thola Biotechnologies is a subsidiary of Elu Healthcare Holdings, an African based biotechnology company that was formed to provide solutions to the medical services sector, born out of the Coronavirus pandemic.
Thola Biotechnologies © 2021 | Website Design by Versys Media